Bone Biologics Corp. (NASDAQ:BBLG) Shares Shorted: Short Interest Down 54.0% in October

Bone Biologics Corp. (NASDAQ:BBLG) was the recipient of a significant decline in short interest during the month of October. As of October 15th, there was short interest totaling 22,777 shares, a decline of 54.0% from the September 30th total of 49,512 shares. Based on an average trading volume of 41,660 shares, the short-interest ratio is currently 0.5 days. Currently, 0.9% of the shares of the stock are short sold.

Bone Biologics Stock Down 3.7%

Shares of BBLG stock traded down $0.01 during trading hours on Friday, hitting $0.37. 12,575 shares of the company’s stock traded hands, compared to its average volume of 143,626. The stock has a market cap of $1.27 million, a PE ratio of -0.32 and a beta of 0.90. The stock’s 50 day simple moving average is $0.50 and its 200 day simple moving average is $1.07. Bone Biologics has a 12 month low of $0.36 and a 12 month high of $2.39.

Bone Biologics (NASDAQ:BBLG) last issued its quarterly earnings data on Monday, October 26th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.02. As a group, equities research analysts expect that Bone Biologics will post -1.23 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Bone Biologics in a report on Thursday, October 22nd. One research analyst has rated the stock with a Sell rating. According to MarketBeat.com, the company has a consensus rating of “Sell”.

About Bone Biologics

Bone Biologics Corporation is a biotechnology and medical device company focused on developing regenerative products for bone repair and spinal fusion. Its technology platform is based on NELL-1, a recombinant human protein designed to stimulate bone growth and support the formation of new bone.

The company’s lead development programs combine NELL-1 with resorbable bone-graft scaffolds for use in orthopedic and spinal procedures. These products are intended to provide surgeons with alternatives or supplements to conventional bone-grafting approaches, with an initial emphasis on spinal fusion applications.

Bone Biologics has conducted its research and development activities in collaboration with academic and medical institutions, including researchers associated with the University of California, Los Angeles.